X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: COMP360
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2021
Details:
The trial is controlled, double-blinded, dose-ranging study, investigating the safety & efficacy of psilocybin therapy & comparing 25mg and 10mg dose of COMP360 psilocybin with 1mg dose, administered in conjunction with psychological support from specially trained therapists.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: COMP360
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2021
Details:
Participants were randomised in a 1:1:1 ratio to receive 10mg COMP360 (n=30), 25mg COMP360 (n=30), or placebo (n=29). The drug was administered simultaneously to upto six participants, who all received 1:1 psychological support from trained therapists throughout the session.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): N-methyl amisulpride
Therapeutic Area: Psychiatry/Psychology Product Name: LB-102
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 25, 2020
Details:
Proceeds to enable the Company’s continued clinical development of LB-102 for the treatment of schizophrenia.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
